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Erenumab (AMG 334) in episodic
migraine
Interim analysis of an ongoing open-label study
ABSTRACT
Objective: To assess long-term safety and efficacy of anti–calcitonin gene-related peptide recep-
tor erenumab in patients with episodic migraine (EM).
Methods: Patients enrolled in a 12-week, double-blind, placebo-controlled clinical trial
(NCT01952574) who continued in an open-label extension (OLE) study will receive erenumab
70 mg every 4 weeks for up to 5 years. This preplanned interim analysis, conducted after all par-
ticipants had completed the 1-year open-label follow-up, evaluated changes in monthly migraine
days (MMD), achievement of $50%, $75%, and 100% reductions, Headache Impact Test (HIT-
6) score, Migraine-Specific Quality of Life (MSQ), Migraine Disability Assessment (MIDAS), and
safety. Data reported as observed without imputation for missing data.
Results: Of 472 patients enrolled in the parent study, 383 continued in the OLE with a median
exposure to erenumab of 575 days (range 28–822 days). Mean (SD) MMD were 8.8 (2.6) at
parent study baseline, 6.3 (4.2) at week 12 (beginning of OLE), and 3.7 (4.0) at week 64 (mean
change from baseline [reduction] of 5.0 days). At week 64, 65%, 42%, and 26% achieved
$50%, $75%, and 100% reduction in MMD, respectively. Mean HIT-6 scores were 60.2
(6.3) at baseline and 51.7 (9.2) at week 64. MSQ and MIDAS improvements from baseline were
maintained through week 64. Safety profiles during the OLE were similar to those in the double-
blind phase, which overall were similar to placebo.
Conclusions: One-year efficacy, supported by functional improvements and favorable safety and
tolerability profiles, supports further investigation of erenumab as a preventive treatment in pa-
tients with EM.
Clinicaltrials.gov identifier: NCT01952574.
Classification of evidence: This study provides Class IV evidence that for patients with episodic
migraine, erenumab reduces long-term MMD and improves headache-related disability and
migraine-specific quality of life. Neurology® 2017;89:1237–1243
GLOSSARY
AE 5 adverse event; CGRP 5 calcitonin gene-related peptide; EF 5 emotional function; EM 5 episodic migraine; HIT-6 5
Headache Impact Test;MIDAS5Migraine Disability Assessment;MMD5monthly migraine days;MSQ5Migraine-Specific
Quality of Life; OLE 5 open-label extension; RFP 5 role function–preventive; RFR 5 role function–restrictive; SC 5
subcutaneously.
Migraine is a disabling neurologic disorder, often accompanied by nausea, vomiting, photopho-
bia, and phonophobia,1 affecting approximately 10% of the US population.2 Although at least
one-third of individuals with episodic migraine (EM) and almost all patients with chronic
migraine should receive preventive drug treatment,3 the majority do not receive preventive drug
treatment. Over 80% of patients do not adhere to or persist with treatment 1 year after starting
preventive medication.4 The suboptimal efficacy and tolerability of available preventive treat-
ments, none of which was designed to treat migraine, are well-known and contribute to poor
compliance and adherence.5 Migraine-specific preventive treatment is a major unmet need.
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Erenumab (AMG 334) is a human mono-
clonal antibody that blocks the calcitonin
gene-related peptide (CGRP) receptor.6 CGRP
is a neuropeptide that plays a key role in
migraine pathogenesis.7 Although the exact
mechanism by which CGRP contributes to
migraine attacks has not been fully elucidated,
there is ample clinical evidence showing that
CGRP and the CGRP receptor are suitable
targets to prevent migraine.7 Although multiple
studies have demonstrated clinical responses to
antibodies targeting CGRP signaling,8–11 there
have been no studies of the long-term safety
and efficacy of these treatments. Here we report
the preplanned interim results from an ongoing
(up to 5 years) open-label extension (OLE)
study of patients completing a 12-week,
placebo-controlled, phase 2 study of erenumab
for EM.8 At the time of analysis, all patients
have either received open-label erenumab 70
mg every 4 weeks for at least 1 year or have
discontinued treatment.
METHODS Study design. The parent study for this OLE
was a 12-week, double-blind, placebo-controlled clinical trial.8
In the parent study, patients received erenumab monthly at 7, 21,
or 70 mg administered subcutaneously (SC) or placebo. Patients
who enrolled in the OLE study received erenumab at 70 mg SC
monthly. This was a preplanned analysis of data once all patients
completed at least 52 weeks of follow-up of the OLE study (week
64 overall) or discontinued open-label erenumab. Efficacy data
were collected only up to 1 year of open-label erenumab, while
safety data continued to be collected.
Patients. Eligibility criteria for enrollment in the parent study
have been reported previously.8 Briefly, key inclusion criteria
included age $18 and #60 years with history of migraine based
on International Classification of Headache Disorders, second
edition,1 for $12 months prior to screening, with at least 4
and #14 migraine days per month and ,15 headache (migraine
and nonmigraine) days per month. Patients could have failed up
to 2 previous preventive therapies due to efficacy. To be eligible
to continue in the OLE phase, patients had to complete the
double-blind treatment phase and not discontinue investiga-
tional product early, and continue to provide informed consent;
continued treatment had to be considered appropriate by the
investigator. In addition, the investigators had to consider
appropriateness of continued treatment for patients who devel-
oped any unstable or clinically significant medical condition,
laboratory or ECG abnormality, or experienced a serious adverse
event (AE) that could reasonably be related to study drug fol-
lowing randomization into the double-blind treatment phase.
Study outcomes. Efficacy endpoints for the OLE phase included
change in monthly migraine days, achievement of$50%,$75%,
and 100% reduction in monthly migraine days, and change in
migraine-specific medication use for the last respective month.
Patient-reported outcomes included the change in Headache
Impact Test (HIT-6) score, Migraine-Specific Quality of Life
(MSQ), and Migraine Disability Assessment (MIDAS). HIT-6
andMSQ data were collected every 4 weeks, andMIDAS was col-
lected at weeks 12, 24, 36, 52, and 64. The HIT-6 is a short-form
self-administered questionnaire that was developed as a global
measure of adverse headache effect to assess headache severity
in the previous month and change in a patient’s clinical status
over a short period of time.12,13 Six questions cover severe pain,
limitation of daily activity (household, work, school, and social),
wanting to lie down when headache is experienced, feeling too
tired to work or do daily activities because of headache, feeling fed
up or irritated because of headache, and headache limiting ability
to concentrate or work on daily activities.12,13 HIT-6 scores are
categorized into 4 grades, representing little or no effect (#49),
some effect (50–55), substantial effect (56–59), and severe effect
(60–78) due to headache.12,13 The within-person minimally
important change for the HIT-6 score is $5 points and the
between-group minimally important difference is estimated to
be 2.3 points.14 The MSQ (version 2.1) is a self-administered
14-item instrument measuring 3 dimensions: role function–
restrictive (RFR; 7 items assessing how migraines limit daily
Table 1 Demographics, clinical characteristics, and patient-reported outcome
scores at baseline of the parent study for patients who entered the
open-label extensiona
All patients (n 5 383)
Age, y, mean (SD) 41.3 (10.9)
Female, n (%) 303 (79)
White race, n (%) 354 (92)
Age at migraine onset, y, mean (SD) 20.9 (11.3)
Duration of disease, y, mean (SD) 20.9 (11.9)
History of migraine with aura, n (%) 137 (36)
Monthly migraine days, mean (SD) 8.7 (2.7)
Monthly headache days, mean (SD) 9.8 (2.7)
Monthly migraine-specific medication days,b mean (SD) 4.3 (3.7)
Prior prophylactic history, n (%)
Naive 214 (56)
Prior use 169 (44)
Treatment failurec 138 (36)
Other 31 (8)
HIT-6, median score (Q1, Q3) 61.0 (56.0, 64.0)
MSQ, median score (Q1, Q3)
MSQ-RFR 60.0 (48.6, 71.4)
MSQ-RFP 75.0 (65.0, 90.0)
MSQ-EF 73.3 (60.0, 86.7)
MIDAS, median score (Q1, Q3)
Total score 22.0 (11.0, 38.0)
Absenteeism 10.0 (5.0, 19.0)
Presenteeism 10.0 (5.0, 19.0)
Abbreviations: EF 5 emotional function; HIT 5 Headache Impact Test; MIDAS 5 Migraine
Disability Assessment; MSQ 5 Migraine-Specific Quality of Life; Q1 5 first quartile; Q3 5
third quartile; RFP 5 role function–preventive; RFR 5 role function–restrictive.
a Baseline was prior to the parent study double-blind phase.
bMigraine-specific medications were triptans and ergot amine-derivative. A total of 259
(68%) patients received triptans and 4 (1%) patients received ergotamine derivatives
during the baseline period.
c Treatment failure included discontinuation due to lack of efficacy or side effects.
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social and work-related activities), role function–preventive (RFP;
4 items assessing how migraines prevent these activities), and
emotional function (EF; 3 items assessing the emotions associated
with migraines).15,16 Raw dimension scores are computed as
a sum of item responses and rescaled from a 0 to 100 scale; higher
scores indicate better quality of life.15,16 The MIDAS is a 5-item
self-administered questionnaire that sums the number of produc-
tive days lost over the last 3 months in the workplace and the
home.17 The MIDAS also assesses disability in family, social, and
leisure activities.17 The MIDAS score is the sum of missed days
due to a headache from paid work, housework, and nonwork
(family, social, leisure) activities and days at paid work or house-
work where productivity was reduced by at least one-half.17
Safety endpoints included all AEs, clinical laboratory values
and vital signs, and development of anti-erenumab antibodies.
AEs were coded according to the Medical Dictionary for
Regulatory Activities version 18.1,18 and severity was graded
using the Common Terminology Criteria for Adverse Events
version 4.03.19 Patient-year adjusted incidence rate was defined
as the total number of patients who reported that event in a given
time period of follow-up divided by total patient-years of expo-
sure in that period. Total patient-years of exposure was defined as
the sum of the number of patients times the duration of exposure
from first erenumab dose to last erenumab dose, end of study, or
first report of event.
Statistical considerations. All patients who received at least 1
dose of erenumab in the OLE study were included in the analysis.
Descriptive summaries are provided for efficacy and patient-
reported outcomes. AEs are summarized as the exposure-
adjusted patient incidence rate per 100 patient-years. Data are
reported as observed, without imputation for missing data.
Primary research question. Does erenumab treatment reduce
monthly migraine days and improve patient-reported outcomes?
This study provides Class IV evidence that for patients with EM,
erenumab reduces long-term monthly migraine days (MMD) and
improves headache-related disability and migraine-specific quality
of life.
Standard protocol approvals, registrations, and patient
consents. This trial is registered with ClinicalTrials.gov (NCT
01952574). All procedures were approved by institutional review
boards at all participating sites. Patients provided written
informed consent.
RESULTS Patients. Of 472 patients who received
erenumab or placebo in the parent study, 383 pa-
tients entered into the OLE study. A total of 307 pa-
tients (80%) completed 1 year of open-label
treatment. At the time of this analysis, 273 (71%)
were continuing investigational product, 3 (1%)
received their last scheduled dose of OLE investiga-
tional product at week 48 (planned final adminis-
tration based on the original protocol), and 107
(28%) discontinued the investigational product
because of patient request (n5 54), AE (n5 14), lost
to follow-up (n 5 11), lack of efficacy (n 5 11),
noncompliance (n 5 4), ineligibility determined
(n 5 1), protocol deviation (n 5 1), or other reasons
(n5 11) (figure e-1 at Neurology.org). The mean age
was 41 years and most patients (79%) were female
(table 1). Clinical characteristics specific to migraine
at baseline were consistent with the patient pop-
ulation with EM (table 1).
Efficacy results. For patients enrolled in the OLE,
mean (SD) monthly migraine days were 8.8 (2.6)
days at baseline (prior to double-blind treatment in
the parent study), 6.3 (4.2) at week 12 (end of
double-blind treatment), and 3.7 (4.0) at week 64
(figure 1A), representing a reduction of 5.0 (4.2)
monthly migraine days. After switching from placebo
or lower erenumab dosages (7, 21 mg) to 70 mg at
week 12 of the parent study, reductions in monthly
migraine days were observed at week 16, the first
efficacy assessment time point of the OLE (figure
e-2). At week 64, 184 (65%) patients had achieved
Figure 1 Changes in monthly migraine days andmigraine-specific medication use
(A) The mean change from baseline in monthly migraine days is shown for patients enrolled in
the parent double-blind study receiving placebo, erenumab 7 mg, erenumab 21 mg, and ere-
numab 70 mg, and for patients in the open-label extension. Error bars represent SE. (B) The
mean change from baseline in monthly migraine-specific medication use is shown for pa-
tients in the parent double-blind study receiving placebo, erenumab 7 mg, erenumab 21
mg, and all patients receiving erenumab 70 mg. Error bars represent SE.
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$50% reduction, 119 (42%) had achieved $75%
reduction, and 73 (26%) had achieved 100%
reduction in monthly migraine days. Mean (SD)
monthly migraine-specific medication days were 4.3
(3.7) at baseline and 2.1 (3.3) at week 64 (figure 1B),
representing a mean reduction of 2.4 monthly
migraine-specific medication days in the OLE phase.
The mean change (SD) from baseline to week 64 in
monthly headache days with moderate/severe pain
was24.7 (4.2) days; in monthly migraine attacks was
22.9 (2.5) attacks; in cumulative hours of migraine
pain was 247.4 (57.4) hours; and in cumulative
hours of headache was 248.9 (60.1) hours.
Patient-reported outcomes. The mean (SD) HIT-6 total
score was 60.2 (6.3) at baseline and 51.7 (9.2) at week
64. Mean change from baseline is shown in figure 2.
Improvements in HIT-6 total score were maintained
through week 64 with 187 (64%) patients achieving
$5-point reduction (the within-person minimally
important change) in HIT-6 score. MSQ-RFR, MSQ-
RFP, and MSQ-EF scores improved from baseline and
were maintained through week 64 (figure 2). Similarly,
MIDAS total score, presenteeism, and absenteeism
improved from baseline and were maintained through
week 64 (figure 2). These improvements on traditional
patient-reported outcomes paralleled the observed re-
ductions in MMD.
Safety. Median erenumab exposure during the open-
label phase was 575 days (range 28–822 days) with
a total exposure of 555.4 patient-years. Overall, 300
patients reported AEs throughout the OLE study for
an exposure-adjusted patient rate of 140.6 per 100
patient-years, which is less than the placebo and ere-
numab 70 mg rates observed during the 12-week
double-blind treatment period (table 2). The types
and natures of AEs and the incidence rates were
comparable with previous observations and did not
reveal any new safety concerns. There were no clini-
cally significant changes in vital signs, laboratory val-
ues, or ECG findings during the OLE. A single event
each of arteriosclerosis and myocardial ischemia were
reported in the OLE study. The arteriosclerosis event
was a fatal event in a 52-year-old man with history of
migraine with aura, and was confounded by preexist-
ing cardiovascular risk factors. The patient had a 3-year
history of diagnosed hypertension with prior treatment
with lisinopril and hydrochlorothiazide, obesity (body
mass index 37 kg/m2), a screening low-density
Figure 2 Change in Headache Impact Test (HIT-6) total score, Migraine-Specific Quality of Life (MSQ) scores, and Migraine Disability
Assessment (MIDAS) scores
(A) The change from baseline in mean HIT-6 total score is shown for patients on placebo (blue line), erenumab 7mg (red line), erenumab 21mg (green line), and
erenumab 70mg (purple line) during the double-blind parent study and for all patients on erenumab 70mg (purple line) during the open-label extension (OLE).
Error bars represent SE. The changes from baseline in mean (B) MSQ–role function–restrictive; (RFR) score, (C) MSQ–role function–preventative (RFP) score,
(D) MSQ–emotional function (EF) score, (E) MIDAS total score, (F) MIDAS presenteeism, and (G) MIDAS absenteeism are shown for patients on placebo (blue
line), erenumab 7 mg (red line), erenumab 21 mg (green line), and erenumab 70 mg (purple line) during the double-blind parent study and for all patients on
erenumab 70 mg (purple line) during the OLE. Error bars represent SE.
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lipoprotein level of 153 mg/dL, left anterior hemiblock
on baseline ECG, and a family history of myocardial
infarction. Autopsy showed evidence of severe coronary
atherosclerosis and presence of cardiac stimulants
(phenylpropanolamine and norpseudoephedrine) in the
liver; this event was considered not related to treatment
per the investigator. The myocardial ischemia event was
based on results of an exercise treadmill test (performed
to evaluate exercise-induced dyspnea), which showed
transient exercise-induced myocardial ischemia (ST
segment depression on ECG, angina was not reported).
However, this case was confounded by sumatriptan
administration 4 hours prior to the event. No cardiac
enzymes were reported on the day of the exercise ECG,
but they were normal 4 days prior; coronary angiogra-
phy was subsequently performed and was normal.
Of 382 patients with antibody testing result after
the first erenumab dose, 50 (13.1%) patients enrolled
in the OLE study developed binding (non-neutraliz-
ing) antibodies on at least one occasion, and 29 of the
50 patients had a transient response, with a negative
result at the last time point tested. No patients in
any group had preexisting antibodies prior to the first
erenumab dose. Of 382 patients, 9 (2.4%) patients
were positive for neutralizing antibodies against ere-
numab on at least one occasion; of these, 8 patients
had a transient response. Development of anti-
erenumab antibodies was not associated with any
clinical finding or safety events.
DISCUSSION Erenumab treatment resulted in long-
term durable, stable improvements in disability,
headache effect, and migraine-specific quality of life.
Safety and tolerability profiles during the OLE (total
exposure 555.4 patient-years) were similar to those
observed for erenumab 70 mg in the double-blind
parent study (total exposure 23.9 patient-years) and
overall were similar to placebo (34.1 patient-years) in
the parent study. Discontinuation rates due to AEs
were low, which is in contrast to current migraine
prophylactics that are associated with high discon-
tinuation rates.20–22 In the 8-month OLE of the
pivotal topiramate trials, 28.7% of participants
withdrew and of those withdrawing 42% withdrew
due to an AE.20 The safety data in this analysis were
based on a median exposure of 575 days with 75% of
participants having received erenumab for 474 days.
The mean reduction in monthly migraine days with
erenumab 70 mg persisted through at least 1 year of
open-label treatment. Reductions in monthly
migraine days were evident 4 weeks after patients
switched from placebo or lower erenumab dosages (7,
21 mg) to 70 mg and treatment effect was sustained
throughout the OLE, such that at week 64 patients
experienced a 5.0-day reduction in monthly migraine
days compared to baseline of the parent study. At
week 64, response rates of $50%, $75, and 100%
were achieved by 65%, 42%, and 26% of patients,
respectively. Notably, at the group level there was no
evidence of tachyphylaxis after 1 year of erenumab
treatment.
No new safety concerns were identified during the
OLE. This confirms previous observations from other
studies, where the safety and tolerability profile of
Table 2 Follow-up exposure-adjusted patient rates of adverse events (AEs)
Event, na (r)
Double-blind treatment phase,
placebo (n 5 153)
Double-blind treatment phase,
erenumab 70 mg (n 5 106)
OLE phase, erenumab
70 mg (n 5 383)
All AEs 82 (350.1) 57 (326.2) 300 (140.6)
Common AEs
Nasopharyngitis 12 (33.9) 6 (23.3) 66 (13.4)
Upper respiratory tract infection 3 (8.0) 3 (11.4) 42 (8.0)
Back pain 4 (10.8) 1 (3.8) 27 (5.0)
Influenza 5 (13.5) 1 (3.5) 27 (5.0)
Grade ‡2 37 (117.1) 23 (98.0) 216 (65.1)
Grade ‡3 2 (5.3) 3 (11.5) 47 (9.0)
Serious AEs 0 1 (3.8) 21 (3.8)
AEs leading to discontinuation of IP 2 (5.3) 3 (11.5) 14 (2.5)
Ischemic heart disease/cerebrovascular AEs of interest
Arteriosclerosis 0 0 1 (0.2)
Myocardial ischemia 0 0 1 (0.2)
ECG T-wave inversion 1 (2.7) 0 1 (0.2)
Abbreviations: IP 5 investigational product; OLE 5 open-label extension; r 5 exposure-adjusted rate per 100 patient-years (n/e*100).
a Number of patients reporting at least 1 occurrence of event.
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erenumab were largely comparable to placebo. The
events of arteriosclerosis and myocardial ischemia,
which occurred during the uncontrolled OLE period,
were clinically confounded and their relevance uncer-
tain without a placebo comparator, particularly given
that cardiovascular events occur with higher frequency
in migraine patients compared to individuals without
migraine.23 There is a theoretical cardiovascular risk
with inhibition of the CGRP pathway, as CGRP is
among a number of mediators (including substance
P, neurokinins, and nitric oxide) released during ische-
mia that have vasodilatory properties.24 Accordingly,
preclinical and clinical safety studies with erenumab
are being conducted to better characterize the putative
cardiovascular effect of antagonizing the CGRP path-
way. Importantly, in the double-blind placebo-con-
trolled portion of the study, no increased incidence
has been observed for cardiovascular events compared
to placebo and in phase 1 studies of erenumab there
was no effect of erenumab on blood pressure.25,26 In
addition to this OLE, longer-term safety will be as-
sessed in a controlled manner in larger phase 3 studies,
one with a 6-month placebo-controlled phase.
In short-term phase 1 and phase 2 clinical trials of
erenumab (including the double-blind treatment
period of the study reported here), there was a low
incidence of binding and neutralizing anti-
erenumab antibodies. The incidence of anti-
erenumab antibodies remained low throughout the
OLE study. The development of anti-erenumab anti-
bodies has not been associated with any clinical find-
ing or safety events; however, this tolerability profile
of erenumab in patients with EM requires long-
term safety outcomes for confirmation.
A limitation of the study is the lack of a placebo group
for efficacy and safety comparisons. It is therefore diffi-
cult to interpret the possible relatedness of an AEwithout
a placebo arm, and it is difficult to distinguish spontane-
ously occurring AEs from AEs due to erenumab. How-
ever, the OLE study is ongoing and will continue to
provide a long-term safety experience for erenumab.
Retention rates, efficacy, patient-reported out-
comes, and safety results after 1 year for erenumab
in patients with EM are promising. These data sup-
port further investigation of erenumab as a potential
preventive treatment option for patients with EM.
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